Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults

Amy Y. Wang, MD, MPH; Lori S. Muffly, MD, MS; Wendy Stock, MD


J Oncol Pract. 2020;16(5):231-238. 

In This Article


Efforts to improve survival and health outcomes in AYA patients with B-cell ALL have intensified over the last 10 years. Discoveries of different biological subtypes and advancements in diagnostics and disease monitoring have guided prognosis and selection of therapy. Incorporation of pediatric-inspired regimens into the front-line setting have begun to shift the survival cliff, as have antibody- and cell-based therapies, which remain an intensive area of research. Minimal residual disease monitoring has become standard and is used to guide prognostication and therapeutic decision making. For progress to continue in this field, it is imperative that AYAs enroll in clinical trials. Hence, the management of AYA ALL has become increasingly more complex, and a multidisciplinary team is needed to address the treatment-related, psychosocial, and supportive care issues that accompany the care of this truly vulnerable patient population.